The relationship between the epidermal growth factor (EGF) 5′UTR variant A61G and melanoma/nevus susceptibility

Journal of Investigative Dermatology

Volumn 123, Issue 4, 2004, Pages 755-759

  Randerson Moor, Juliette A ^a   Gaut, Rupert ^a   Turner, Faye ^a   Whitaker, Linda ^a   Barrett, Jenny H ^a   Dos Santos Silva, Isabel ^b   Swerdlow, Anthony J ^c   Bishop, David T ^a   Newton Bishop, Julia A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Breslow thickness; EGF; Melanoma; Nevus; Polymorphism

Indexed keywords

EPIDERMAL GROWTH FACTOR;

5' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; ATYPICAL MOLE SYNDROME; CANCER GENETICS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; INHERITANCE; MAJOR CLINICAL STUDY; MALE; MELANOMA; NEVUS; PENETRANCE; PHENOTYPE; PIGMENTED NEVUS; PREDICTION; PRIORITY JOURNAL;

EID: 4644338277     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.23304.x     Document Type: Article

References (30)

1. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N: CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 91:446-52, 1999
2. Bataille V, Bishop JA, Sasieni P, Swerdlow AJ, Pinney E, Griffiths K, Cuzick J: Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: A case-control study. Br J Cancer 73:1605-11, 1996
3. Bertram CG, Gaut RM, Barrett JH, et al: An Assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 119:961-965, 2002
4. Bertram CG, Gaut RM, Barrett JH, et al: An assessment of a variant of the DNA repair gene XRCC3 as a possible nevus or melanoma susceptibility genotype. J Invest Dermatol 122:429-432, 2004
5. Box NF, Duffy DL, Chen W, Stark M, Martin NG, Sturm RA, Hayward NK: MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69:765-73, 2001
6. Dolzan V, Rudolf Z, Breskvar K: Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 16:2675-2678, 1995
7. Duan Z, Shen H, Lee JE, et al: DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 11 (Part 1):1142-3, 2002
8. Easton D, Cox G, Macdonald A, Ponder B: Genetic susceptibility to naevi - a twin study. Br J Cancer 64:1164-1167, 1991
9. Goldstein AM, Tucker MA: Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 89:676-678, 1997
10. Hutchinson PE, Osborne J E, Lear JT, et al: Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 6:498-504, 2000
11. Kanetsky PA, Holmes R, Walker A, et al: Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. Cancer Epidemiol Biomarkers Prev 10:509-13, 2001
12. Kumar R, Smeds J, Berggren P, Straume O, Rozell BL, Akslen LA, Hemminki K: A single nucleotide polymorphism in the 3′untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare. Int J Cancer 95:388-93, 2001
13. Lafuente A, Molina R, Palou J, Castel T, Moral A, Trias M: Phenotype of glutathione S-transferase Mu (GSTM1) and susceptibility to malignant melanoma. MMM group. Multidisciplinary Malignant Melanoma Group. Br J Cancer 72:324-6, 1995
14. McCarron SL, Bateman AC, Theaker JM, Howell WM: EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma. Int J Cancer 107:673-5, 2003
15. Meyer P, Sergi C, Garbe C: Polymorphisms of the BRAF gene predispose males to malignant melanoma. J Carcinog 2:7, 2003
16. Newton Bishop JA, Bataille V, Pinney E, Bishop DT: Family studies in melanoma: Identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res 4:199-206, 1994
17. Randerson-Moor JA, Harland M, Williams S, et al: A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10:55-62, 2001
18. Shahbazi M, Pravica V, Nasreen N, et al: Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 359:397-401, 2002
19. Shen H, Liu Z, Strom SS, et al: p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol 121:1510-4, 2003
20. StataCorp (2001). Statistical software: Release 7.0. Stata College Station, TX: Stata Corporation.
21. Strange RC, Ellison T, Ichii-Jones F, et al: Cytochrome P450 CYP2D6 genotypes: Association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 9:269-76, 1999
22. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JAA, Clarke J, Hole DJ: Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J 292:1555-1560, 1986
23. Tomescu D, Kavanagh G, Ha T, Campbell H, Melton DW: Nucleotide excision repair gene XPD polymorphisms and genetic predisposition to melanoma. Carcinogenesis 22:403-408, 2001
24. Valverde P, Healy E, Sikkink S, et al: The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Human Mol Genet 5:1663-1666, 1996
25. van der Velden PA, Sandkuijl LA, Bergman W, Pavel S, van Mourik L, Frants RR, Gruis NA: Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69:774-779, 2001
26. Wachsmuth RC, Gaut RM, Barrett JH, et al: Heritability and gene-environment interactions for melanocytic nevus density examined in a U.K. adolescent twin study. J Invest Dermatol 117:348-352, 2001
27. Winsey SL, Haldar NA, Marsh HP, et al: A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. Cancer Res 60:5612-5616, 2000
28. Wolf CR, Smith CA, Gough AC, et al: Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13: 1035-1038, 1992
29. Zhu G, Duffy D, Eldridge A, et al: A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: A maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 65:483-492, 1999
30. Zuo L, Weger J, Yang Q, et al: Germline mutations in the p161NK4a binding domain of CDK4 in familial melanoma. Nature Genetics 12:97-99, 1996